HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

gatifloxacin (Zymar)

Subscribe to New Research on gatifloxacin

gatifloxacin is (+-)-isomer; structure in first source

Also Known As:

Zymar; Tequin; 1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; AM 1155; AM-1155; BMS-206584; CG 5501; gatifloxacin, (+-)-isomer; gatifloxacine; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-

Networked: 393 relevant articles (77 outcomes, 85 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Quinolines: 92
    - Quinolones: 1190
      - Fluoroquinolones: 2005
        gatifloxacin: 393

Experts

1.	Jones, Ronald N: 8 articles (02/2012 - 09/2002)
2.	Nicholson, Susan C: 8 articles (09/2002 - 06/2002)
3.	Dolecek, Christiane: 6 articles (04/2015 - 01/2007)
4.	Mah, Francis S: 6 articles (01/2011 - 09/2003)
5.	Basnyat, Buddha: 5 articles (04/2015 - 01/2007)
6.	Jensen, Harold: 5 articles (12/2014 - 09/2003)
7.	Moshirfar, Majid: 5 articles (10/2008 - 03/2006)
8.	Romanowski, Eric G: 5 articles (08/2008 - 09/2003)
9.	Gordon, Y Jerold: 5 articles (08/2008 - 09/2003)
10.	Kowalski, Regis P: 5 articles (08/2008 - 09/2003)

Related Diseases

1.	Infection 11/01/1997 - "These results suggest that the clinical efficacy of AM-1155 against infections involving most anaerobic bacteria except for the B. " 06/01/2002 - "The magnitude of the 24-h AUC/MIC of gatifloxacin required for efficacy against multiple pathogens varied only fourfold and was not significantly altered by drug resistance or site of infection." 08/18/2008 - "The results indicated that gatifloxacin is still effective against MRSA isolates and might be useful for treatment of less serious MRSA infections but careful monitoring of susceptibility is required." 03/01/2005 - "Gatifloxacin is an 8-methoxy fluoroquinolone effective against a broad spectrum of pathogens common in pediatric infections. " 01/01/2001 - "Gatifloxacin should prove to be a safe and effective agent for a wide variety of infections."
2.	Pneumonia (Pneumonitis) 09/01/2002 - "To evaluate the safety and efficacy of gatifloxacin in adults <65, 65 to 79, or > or =80 years old with community-acquired pneumonia, adult male and female outpatients from general community-based practices were enrolled in an open-label, multicenter, noncomparative study. " 09/01/2004 - "In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants." 09/01/2002 - "Gatifloxacin is an advanced-generation fluoroquinolone with demonstrated efficacy and safety as therapy for community-acquired pneumonia (CAP). " 10/01/2007 - "To consider the optimized administration method based on PK/PD theory for the elderly patients of gatifloxacin (GFLX), which was one of the oral respiratory quinolone antibacterial, Monte Carlo Simulation was conducted with community-acquired pneumonia and susceptibility data for Streptococcus pneumoniae (345 strains) collected by the second gatifloxacin surveillance study. " 02/01/2003 - "An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers."
3.	Keratitis 11/01/2013 - "Gatifloxacin 0.3% ophthalmic solution due to its strong activity against various gram-positive and gram-negative microbes is strongly effective in the treatment of acute bacterial keratitis." 04/01/2010 - "Topical gatifloxacin 0.3% may be successfully used to treat microbial keratitis resulting from atypical mycobacteria." 06/01/2007 - "Zymar may prove useful for SM and PA keratitis." 07/01/2005 - "The fourth-generation fluoroquinolone, gatifloxacin, could be effectively used for the treatment of mycobacterial keratitis." 08/01/2004 - " Relevance Topical gatifloxacin 0.3% may provide an initial alternative in therapy of M chelonae keratitis."
4.	Urinary Tract Infections (Urinary Tract Infection) 10/01/1992 - "AM-1155 also had good efficacy against mouse ascending urinary tract infections with Escherichia coli and P. " 03/01/2000 - "These results suggest that gatifloxacin may be useful in the treatment of urinary tract infections." 04/01/2009 - "To assess the clinical efficacy of oral antibiotic administration for the treatment of lower urinary tract infection (UTI), 102 female patients were given gatifloxacin (200 mg once daily for 3 days). " 08/01/2006 - "Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice." 03/01/2006 - "A 48-year-old man participating in a residential treatment program was treated with gatifloxacin for a urinary tract infection. "
5.	Chronic Bronchitis 03/01/2003 - "The results of the study show that gatifloxacin is a safe and effective agent for the treatment of patients with chronic bronchitis experiencing an acute infectious exacerbation." 01/01/2007 - "Based on the findings of this study in small numbers of healthy young adult volunteers and patients with chronic bronchitis, BMS appears to be a promising method for measuring drug concentrations and determining the pharmacokinetic profile of gatifloxacin in bronchial ELF. " 01/01/2007 - "Bronchial ELF samples were obtained by BMS at 1, 2, 3, 4, 6, 10, and 24 hours after administration of a single oral dose of gatifloxacin 200 mg in healthy young adult (aged 20-25 years) subjects, and at 1, 2, 4, and 10 hours after a single dose in patients with chronic bronchitis (aged > or =20 years). " 01/01/2007 - "BMS and BAL were used to analyze the pharmacokinetics of gatifloxacin in bronchial ELF from healthy young adult subjects and adult patients with chronic bronchitis. " 01/01/2007 - "Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage."

Related Drugs and Biologics

1.	moxifloxacin (Avelox)
2.	Ciprofloxacin (Cipro)
3.	Ofloxacin (Levofloxacin)
4.	gatifloxacin (Zymar)
5.	Amoxicillin (Wymox)
6.	Clarithromycin (Biaxin)
7.	Quinolones
8.	Clavulanic Acid (Potassium Clavulanate)
9.	Azithromycin (Zithromax)
10.	Tobramycin (Nebcin)

Related Therapies and Procedures

1.	Topical Administration
2.	Laser In Situ Keratomileusis (LASIK)
3.	Oral Administration
4.	Dry Powder Inhalers
5.	Transplants (Transplant)